2096-9511

Infectious Diseases & Immunity

Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins

View prefix report (10.1097)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 215 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact215 DOIs
2

Add abstracts to 54 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact54 DOIs
3

Deposit reference lists for 7 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact7 DOIs

DOIs for this ISSN

Showing the top 5 of 217 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Guidelines for the Prevention, Diagnosis, Care and Treatment… (10.1097/id9.0000000000000128)
Abstract References ORCID
118.48 37
2 WHO-Convened Global Study of Origins of SARS-CoV-2: China Pa… (10.1097/id9.0000000000000017)
Abstract References ORCID
102.13 22
3 Diagnosis and Treatment Protocol for COVID-19 Patients (Tent… (10.1097/01.id9.0000733564.21786.b0)
Abstract References ORCID
97.58 19
4 Diagnosis and Treatment Protocol for COVID-19 Patients (Tent… (10.1097/id9.0000000000000059)
Abstract References ORCID
95.91 18
5 Diagnosis and Treatment Protocol for COVID-19 Patients (Tent… (10.1097/id9.0000000000000002)
Abstract ORCID
68.09 22
6 Origins of SARS-CoV-2: Focusing on Science (10.1097/id9.0000000000000008)
Abstract ORCID
55.70 12
7 The Arms Race in the War Between Virus and Host: Implication… (10.1097/id9.0000000000000062)
Abstract ORCID
50.00 9
8 Advances in Research on COVID-19 Vaccination for People Livi… (10.1097/id9.0000000000000065)
Abstract ORCID
47.71 8
9 AIDS, crisis and power to transform (Text extract): UNAIDS g… (10.1097/id9.0000000000000176)
Abstract ORCID
45.15 7
10 Human Immunodeficiency Virus/Acquired Immunodeficiency Syndr… (10.1097/id9.0000000000000126)
Abstract ORCID
42.25 6
11 Chinese Guidelines for the Diagnosis and Treatment of HIV/AI… (10.1097/id9.0000000000000044)
ORCID
36.18 27
12 Expert Consensus on the Prevention and Treatment of Hemorrha… (10.1097/id9.0000000000000054)
ORCID
31.97 18
13 Development and Evaluation of a Promising Biomarker for Diag… (10.1097/id9.0000000000000104)
ORCID
29.40 14
14 Changes of Damage Associated Molecular Patterns in COVID-19… (10.1097/01.id9.0000733572.40970.6c)
ORCID
25.00 9
15 Identifying Malaria Hotspots Regions in Ghana Using Bayesian… (10.1097/id9.0000000000000116)
ORCID
25.00 9
16 Innate Immune Response in Respiratory System: A Double-edged… (10.1097/id9.0000000000000031)
Abstract ORCID
23.86 2
17 Advances and Challenges of Epidemic Outbreaks in the Post-CO… (10.1097/id9.0000000000000086)
Abstract ORCID
23.86 2
18 Immunosenescence and its related comorbidities in older peop… (10.1097/id9.0000000000000134)
ORCID
23.86 8
19 Serological Detection of West Nile Virus in Single-Humped Ca… (10.1097/id9.0000000000000135)
Abstract ORCID
23.86 2
20 HHV-6 reactivations in immunocompetent patients with psychia… (10.1097/id9.0000000000000154)
Abstract ORCID
23.86 2
21 ACE2 and TMPRSS2 Expression in Hepatocytes of Chronic HBV In… (10.1097/id9.0000000000000007)
ORCID
21.13 6
22 Systematic Discovery and Pathway Analyses of Metabolic Distu… (10.1097/id9.0000000000000010)
ORCID
21.13 6
23 “Elimination of Hepatitis by 2030”: Present Realities and Fu… (10.1097/id9.0000000000000028)
ORCID
21.13 6
24 Potential of Antibody-Dependent Cellular Cytotoxicity in Acu… (10.1097/id9.0000000000000053)
ORCID
21.13 6
25 Role of CRISPR-Cas system as a new approach in fighting the… (10.1097/id9.0000000000000149)
ORCID
21.13 6
26 The COVID-19 Vaccine in Clinical Trials: Where Are We Now? (10.1097/id9.0000000000000003)
ORCID
19.45 5
27 Diagnosis and Treatment Guidelines for Mesenchymal Stem Cell… (10.1097/id9.0000000000000016)
ORCID
19.45 5
28 Guidelines for the Diagnosis and Treatment of Dengue in Chin… (10.1097/id9.0000000000000026)
ORCID
19.45 5
29 The Rational Combination Strategy of Immunomodulatory Latenc… (10.1097/id9.0000000000000045)
ORCID
19.45 5
30 Inflammasomes in Human Immunodeficiency Virus Type 1 Infecti… (10.1097/id9.0000000000000070)
ORCID
19.45 5
31 Expert Consensus on the Prevention and Treatment of Chronic… (10.1097/id9.0000000000000122)
ORCID
19.45 5
32 Viral persistence in long COVID: Research advances and treat… (10.1097/id9.0000000000000163)
ORCID
19.45 5
33 Reinfection and Breakthrough Infection of SARS-CoV-2: An Eme… (10.1097/id9.0000000000000027)
ORCID
17.47 4
34 Effectiveness and Controversy of Convalescent Plasma Therapy… (10.1097/id9.0000000000000033)
ORCID
17.47 4
35 Highly Prevalent SARS-CoV-2 Antigenemia in COVID-19 Patients (10.1097/id9.0000000000000057)
ORCID
17.47 4
36 Difference of Clinical Characteristics in Patients with Omic… (10.1097/id9.0000000000000081)
ORCID
17.47 4
37 Epidemiology, natural history, and outcome of chronic hepati… (10.1097/id9.0000000000000130)
ORCID
17.47 4
38 Interpretation of guidelines for diagnosis, management, and… (10.1097/id9.0000000000000141)
ORCID
17.47 4
39 SARS-CoV-2 Variants: Surveillance, Evaluation, and Challenge… (10.1097/id9.0000000000000019)
Abstract ORCID
15.05 1
40 Risk Factors for Severity and Mortality in Adult Patients Co… (10.1097/id9.0000000000000037)
ORCID
15.05 3
41 Publishing clinical prActice GuidelinEs (PAGE): Recommendati… (10.1097/id9.0000000000000063)
ORCID
15.05 3
42 Glucose Metabolism and Human Immunodeficiency Virus Type 1 I… (10.1097/id9.0000000000000071)
ORCID
15.05 3
43 Lipid-Based Poly(I:C) Adjuvants Strongly Enhance the Immunog… (10.1097/id9.0000000000000074)
ORCID
15.05 3
44 Characteristics and Potential Roles of Natural Killer Cells… (10.1097/id9.0000000000000075)
ORCID
15.05 3
45 Problems and Challenges Associated with Renaming Non-alcohol… (10.1097/id9.0000000000000085)
ORCID
15.05 3
46 Flux Balance Analysis Reveals Potential Anti–HIV-1 Metabolic… (10.1097/id9.0000000000000109)
ORCID
15.05 3
47 Challenges and Strategies for Influenza Response After COVID… (10.1097/id9.0000000000000117)
Abstract ORCID
15.05 1
48 Co-infection with hepatitis B and human immunodeficiency vir… (10.1097/id9.0000000000000123)
ORCID
15.05 3
49 CAR-T Therapy in HIV: Pioneering Advances and Navigating Cha… (10.1097/id9.0000000000000129)
ORCID
15.05 3
50 Safety Profile of COVID-19 Vaccines in HIV Patients Undergoi… (10.1097/id9.0000000000000138)
ORCID
15.05 3